Literature DB >> 27034417

Alleviating the storm: ruxolitinib in HLH.

Paul La Rosée1.   

Abstract

In this issue of Blood, Das and colleagues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murine models of hemophagocytic lymphohistiocytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27034417     DOI： 10.1182/blood-2016-02-697151

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  7 in total

1.  Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry.

Authors:  Sebastian Birndt; Thomas Schenk; Babett Heinevetter; Frank M Brunkhorst; Georg Maschmeyer; Frank Rothmann; Thomas Weber; Markus Müller; Jens Panse; Olaf Penack; Roland Schroers; Jan Braess; Norbert Frickhofen; Stephan Ehl; Gritta Janka; Kai Lehmberg; Mathias W Pletz; Andreas Hochhaus; Thomas Ernst; Paul La Rosée
Journal:  J Cancer Res Clin Oncol       Date:  2020-02-20       Impact factor: 4.553

Review 2.  The amount of cytokine-release defines different shades of Sars-Cov2 infection.

Authors:  S Bindoli; M Felicetti; P Sfriso; A Doria
Journal:  Exp Biol Med (Maywood)       Date:  2020-05-28

Review 3.  Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature.

Authors:  Steve Hu; Pranshu Bansal; David Lynch; Cristhiam Mauricio Rojas Hernandez; Zoneddy Dayao
Journal:  J Med Case Rep       Date:  2016-12-20

Review 4.  Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases.

Authors:  Marie von Lilienfeld-Toal; Jörg Janne Vehreschild; Oliver Cornely; Livio Pagano; Francesca Compagno; Hans H Hirsch
Journal:  Leukemia       Date:  2020-05-01       Impact factor: 11.528

Review 5.  COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.

Authors:  H C Hasselbalch; V Skov; L Kjær; C Ellervik; A Poulsen; T D Poulsen; C H Nielsen
Journal:  Cytokine Growth Factor Rev       Date:  2021-04-14       Impact factor: 7.638

6.  Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis.

Authors:  Zhaoling Wang; Qi Zheng; Wenjie Xuan; Xisheng Xu; Meiping Lu; Jianqiang Wu; Lixia Zou; Yiping Xu; Xuefeng Xu
Journal:  Front Pediatr       Date:  2022-09-20       Impact factor: 3.569

Review 7.  The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature.

Authors:  Alice Wang; Katelyn Singh; Wael Ibrahim; Brett King; William Damsky
Journal:  Yale J Biol Med       Date:  2020-03-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.